Assenagon Asset Management S.A. Has $66.35 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Assenagon Asset Management S.A. raised its position in DexCom, Inc. (NASDAQ:DXCM) by 53.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 989,740 shares of the medical device company’s stock after buying an additional 345,114 shares during the period. Assenagon Asset Management S.A.’s holdings in DexCom were worth $66,352,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in DXCM. Team Hewins LLC increased its stake in shares of DexCom by 3.4% in the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after buying an additional 83 shares in the last quarter. Bleakley Financial Group LLC increased its position in DexCom by 1.3% in the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after acquiring an additional 87 shares in the last quarter. Capital Insight Partners LLC raised its stake in shares of DexCom by 2.5% in the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the last quarter. Sound Income Strategies LLC lifted its position in shares of DexCom by 41.7% during the first quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock worth $47,000 after purchasing an additional 100 shares in the last quarter. Finally, HM Payson & Co. grew its stake in shares of DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after purchasing an additional 100 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

Shares of DXCM stock opened at $74.85 on Friday. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The firm has a fifty day moving average of $70.13 and a 200-day moving average of $98.71. The firm has a market capitalization of $29.77 billion, a price-to-earnings ratio of 48.29, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same period in the prior year, the company earned $0.34 earnings per share. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. On average, equities research analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DXCM has been the subject of several research analyst reports. Robert W. Baird boosted their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Stifel Nicolaus boosted their price objective on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Barclays cut their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research report on Monday, July 29th. Finally, Wells Fargo & Company dropped their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $110.73.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the company’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.